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Summary
Background: High mutability of HIV is the driving
force of antiretroviral drug resistance, which repre-
sents a medical care challenge.
Method and Model Equation: To detect
the mutability of each gene in the HIV-1 genome;
a mathematical analysis of HIV-1 genome is per-
formed, depending on a linear relation wherein the
probability of spontaneous mutations emergence is
directly proportional to the ratio of the gene length
to the whole genome length.
PgSi =
g
G
Results: tat, vpr and vpu are the least mu-
tant genes in HIV-1 genome. Protease PROT gene
is the least mutant gene component of polymerases
pol.
Conclusion: tat, vpr and vpu are the best
candidates for HIV-1 recombinant subunit vac-
cines or as a part of “prime and boost” vaccine
combinations. Also; the protease inhibitor-based
regime represents a high genetic barrier for HIV to
overcome.
INTRODUCTION:
Retroviruses depend on their genetic instability as an
evolutionary advantage to boost adaptive mutations.
HIV has a very high genetic variability, which is a
result of its fast replication cycle coupled with a
high mutation rate [1]. HIV is capable of rapidly
responding to the selective pressures imposed by
the immune system and antiretroviral drugs. Drugs
target only specific molecules, which are almost
always proteins. Because the drug is so specific, any
mutation in these molecules will interfere with or
negate its effect, resulting in drug resistance [2].
Biological systems are paramount examples of com-
plex dynamical systems, so mutation emergence is a
fundamental property. The ability to calculate the
probability of spontaneous mutations in a specific
gene, will help provide an overview of the possibility
of emergence of resistance to the protein translated
from that gene during antiviral drug development.
Also, this ability will be beneficial during protocol-
ing of combination therapy.
MODEL EQUATION:
The method used to formulate the mutability map
of HIV-1 genetic pool, is a linear relation in which
the probability of spontaneous mutation emergence,
is directly proportional to the ratio of the gene length
to the whole genome length.
Pg ∝
g
G
And so;
PgSi =
g
G
Wherein;
Pg is the probability of spontaneous mutation emer-
gence in a gene per duplicate.
g
G
is the ratio between the gene length and the whole
genome length.
Si is the stability index, which is a genome specific
fixed value, and so:
PGSi = 1
PG is the probability of spontaneous mutation
emergence in the genome per duplicate.
And so; the stability index represents the degree of
stability of a genome.
The mutation rate of HIV-1 is approximately 3 ×
10−5 per nucleotide base per cycle of replication [3].
The HIV-1 genome contains 9181 bases [4] and ac-
cordingly; the stability index of the HIV-1 genome is:
Si =
1
PG
2So;
Si ≈ 3.63
RESULTS:
A mathematical analysis, using the proposed equa-
tion, is performed and data are collected in 3
tables. Table 1 describes the analysis of the HIV-1
genetic pool, which indicates that the probability
of spontaneous mutation emergence is lesser for
tat, vpr and vpu. Table 2 describes the detailed
analysis of the probability of spontaneous mutations
emergence in the components of pol gene: reverse
transcriptase, integrase and protease genes. These
genes are translated into the main target proteins of
antiretroviral therapy. The analysis indicates that
reverse transcriptase RT is the most mutant gene of
the polymerases and protease PROT is the least.
Table 3 describes the analysis of the structural genes
of gag and env, which indicates that gp120 is more
susceptible to spontaneous mutations emergence, and
so has a higher diversity, than gp41.
Table 1:
Analysis of the probability of spontaneous mutation
in HIV-1 genetic pool; wherein g is the gene length,
Pg is the probability of spontaneous mutation emer-
gence in a specific gene and %PG is % of spontaneous
mutation probability of the genome.
Gene (g) Pg % PG
gag 1502 ≈ 0.049 16.36%
pol 3011 ≈ 0.098 32.8%
vif 569 ≈ 0.017 6.2%
vpr 236 ≈ 0.008 2.57%
tat 259 ≈ 0.008 2.9%
rev 349 ≈ 0.011 3.8%
vpu 248 ≈ 0.008 2.7%
env 2570 ≈ 0.077 28%
nef 371 ≈ 0.012 4%
Table 2:
The probability of spontaneous mutations in RT,
INT and PROT genes of HIV-1, that are translated
into the main target proteins of antiretroviral ther-
apy.
Gene (g) Pg % PG
RT 2078 ≈ 0.067 22.63%
INT 464 ≈ 0.015 5.05%
PROT 296 ≈ 0.01 3.23%
Table 3:
Analysis of the probability of spontaneous mutations
in structural genes gag and env.
Gene mPeptide (g) Pg % PG
gag P17 452 ≈ 0.015 4.9%
P24 692 ≈ 0.022 7.54%
P2 41 ≈ 0.001 0.45%
P7 164 ≈ 0.005 1.79%
P6 155 ≈ 0.005 1.7%
env gp120 1442 ≈ 0.047 15.7%
gp41 1034 ≈ 0.034 11.26%
DISCUSSION:
Spontaneous mutation can arise from a variety of
sources, and whatever the cause is, a large gene
provides a large target and tend to mutate more
frequently. Thus; the probability of spontaneous
mutation is related to the ratio between the gene
length and the whole genome length. This basic
linear relation is used to formulate an equation that
calculates the probability of emergence of spon-
taneous mutation in a certain gene per duplicate,
depending on the ratio between the gene length and
the whole genome length g
G
in addition to the fixed
genome-specific stability index Si.
The drawbacks, which halt the development of
HIV vaccines, are high mutability and variability of
the virus. The mathematical analysis of each gene
in HIV-1 genome (Table 1) indicates that tat, vpr
and vpu are the least mutant genes per duplicate, so
they are the best candidates for HIV-1 recombinant
subunit vaccines or as a part of “prime and boost”
vaccine combinations. Also; the analysis indicates
that the probability percent of spontaneous mutation
emergence in the major three genes of HIV-1 genome
gag, pol and env is 16.36 %, 32.8 % and 28 %
respectively. So; pol gene, which translated into
polymerases enzymes, is the most susceptible gene for
spontaneous mutations. Polymerases are currently
the main targets for antiretroviral therapy and
further analysis of pol gene indicates that reverse
transcriptase RT gene is the most mutant among the
polymerases.
The probability percent of spontaneous mutations
in the RT, accounts for 22.63 % of the total probabil-
ity of spontaneous mutation emergence of the whole
HIV-1 genome. Despite its high mutability; reverse
transcriptase inhibitors should stay as a backbone of
any highly active antiretroviral therapy (HAART).
Reverse transcriptase, and due to its recombogenic
properties and the absence of proofreading activity,
is the core source of mutations in the HIV replication
3cycle. On the other hand; protease PROT gene is
the least mutant in the polymerases. The probability
percent of spontaneous mutations in the PROT
accounts for 3.23 % of the total probability of
spontaneous mutation emergence of the whole HIV-1
genome (Table 2). Accordingly; protease inhibitors
are better candidates, as a base, for antiretroviral
combination therapy and the protease inhibitor-based
regime represents a high genetic barrier for HIV to
overcome.
The proposed mathematical analysis has many
supportive clinical data. For example; The United
Kingdom has one of the highest reported rates of
primary resistance to HIV drugs worldwide. UK
Group on Transmitted HIV Drug Resistance stated
that the prevalence of resistance to any antiretroviral
drug; to nucleoside or nucleotide reverse transcrip-
tase inhibitors (NRTI), to non-nucleoside reverse
transcriptase inhibitors (NNRTI), or to protease
inhibitors (PI) were 19.2 %, 12.4 %, 8.1 %, and
6.6 %, respectively [5]. In Spain; a study stated
that the prevalence was 5.8 % for NRTI, 5 % for
NNRTI and 3.8 % for PI [6]. In Turkey; a study
stated that the percentage of HIV-1 primary drug
resistance mutations, in antiretroviral therapy-naive
patients, was 5.2 % for NRTI, 3.1 % for NNRTI and
2.1 % for PI [7]. In Djibouti; a study indicated that
among 16 patients with first-line ART failure, 56.2
% showed reverse transcriptase inhibitor-resistant
HIV-1 strains. But on the contrary; no protease
inhibitor resistant strains were detected [8]. All
these findings indicate that resistance emergence to
protease inhibitors is much lesser than that of reverse
transcriptase inhibitors.
In a wider scope; the main advantage of the
proposed mathematical approach is providing a
linear equation to calculate the probability of spon-
taneous mutation per duplicate for simpler viral
genomes. Otherwise; further analysis is needed
before recruiting this equation to make a mutability
map for more complicated bacterial or eukaryotic
genomes. If the equation is applicable on these more
complex genomes, it will indicate that noncoding
genome segments, which present in the genome of
prokaryotes and eukaryotes by different portions, not
only perform regulatory functions, but also protect
the genetic information of the coding genome by
providing a wider genetic pool.
Moreover; the proposed equation is useful for an-
tiviral drug activity interpretation, as the mutability
of the targeted protein plays an integral role in
determining in vivo drug activity. Furthermore; the
equation provides a general picture about the muta-
bility of each gene in a targeted viral genome. This
can be helpful during drug development researches,
and during protocoling of combination therapy. The
developers can target proteins translated from the
relatively lesser mutating genes.
On the other hand; the main disadvantage of the
proposed equation is numerical bias during expressing
it with numerical values. As an example; the numer-
ical value of the stability index for HIV-1 genome
can be biased. Mansky and Temin reported that
the forward mutation rate for HIV-1 was 3.4 × 10−5
mutations per bp per cycle [9], while Cuevas et al
used the intrapatient frequency of premature stop
codons to quantify the HIV-1 genome-wide rate
of spontaneous mutation in DNA sequences from
peripheral blood mononuclear cells, which revealed a
mutation rate of (4.1 ± 1.7)× 10−3 per base per cell
[10].
In addition to the fact that the emergence of
antiviral drug resistance is a multifactorial pro-
cess [11]; the proposed equation only provides the
probability of spontaneous mutation emergence in
a specific gene, but does not determine which of
these emergent mutations are lethal and which are
not. The lethally mutated viral genomes fail to reach
the plasma leading to mass deletion of the emergent
mutation.
CONCLUSION:
The mathematical analysis of HIV-1 genome indi-
cates that tat, vpr and vpu are the least mutant
genes per duplicate, so they are the best candidates
for HIV-1 recombinant subunit vaccines or as a part
of “prime and boost” vaccine combinations. Also;
protease inhibitors are better candidates, as a base,
for antiretroviral combination therapy and the pro-
tease inhibitor-based regime represents a high genetic
barrier for HIV to overcome. In a wider scope; The
proposed equation offers a wider array of options
for drug developers and during drug combination
protocoling to help predict in vivo antiviral drug
activity and to deal with mutation-induced drug
resistance.
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